



Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Un	der the Paperwork Reduction Act of 1995, no	persons are required	to respond to a collection of info	ormation unless it displays a valid OMB control number.
PE			Application Number	09/642,609
0 2003	TRANSMITTA	ŀ	Filing Date	August 17, 2000
1	FORM	_	First Named Inventor	KUMAGAI, YOSHINARI 1653 MOHAMED, ABDEL A. BEAR-004
PADEMAN	N. O.		Group Art Unit	1653 EB
AUE	(to be used for all correspondence after in	itial filing)	Examiner Name	MOHAMED, ABDEL A.
	Total Number of Pages in This Submiss	ion	Attorney Docket Number	BEAR-004
		ENCLOSUR	ES (check all that apply)	
	Fee Transmittal Form Fee Attached	1	ment Papers Application) g(s)	After Allowance Communication to Group Appeal Communication to Board
	Amendment / Reply	Linana	ing related Denom	of Appeals and Interferences
	After Final	Licens	ing-related Papers	Appeal Communication to Group
	Affidavits/declaration(s)	Petition	1	(Appeal Notice, Brief, Reply Brief)
	Extension of Time Request		n to Convert to a onal Application	Proprietary Information
	Express Abandonment Request	Power	of Attorney, Revocation	Status Letter
	Information Disclosure Statement	Chang Addres	e of Correspondence	Other Enclosure(s) (please
	Certified Copy of Priority Documents	Termin	al Disclaimer	identify below): 1) Response to Restriction Requirement (2 pgs.)
	Response to Missing Parts/	Reque	st for Refund	2) Return Postcard
	Incomplete Application	CD, Nu	ımber of CD(s)	
	Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks		
	SIGNA	TURE OF APPL	ICANT, ATTORNEY, OR	RAGENT
Firm or Individua	PAULA A. BORDE	N, Reg. No. 42,344	\ \	
Signatur		256		
Date	February 3, 2003			
		CERTIFIC	CATE OF MAILING	
I hereb	y certify that this correspondence is be	ing deposited with	the United States Postal Se	ervice with sufficient postage as first class mail
	nvelope addressed to: Commissioner or printed name (findy Kim Mo)		ngton, DC 20231 on this dai)	te: February 3, 2003.
Signatu	17.7	MI VY		D-to F-b 2 0000

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 1 0 2003 @	•	• •	
	CERTIFICATE OF MAILING		
I hereby certify that this correspondences being deposited with the Patents, Washington, D.C. 20231.	e United States Postal Service as first cla	ss mail in an envelope addressed to: Commissioner for	
Typed or Printed Name	Chaly Houng		
Signature	Date 2/3/03	THE THE	
RESPONSE TO RESTRICTION	Attorney Docket (Confirmation No.)	BEAR004 6929	
REQUIREMENT	First Named Inventor	Y. Kumagai	
Address to:	Application Number	09/642,609	
Commissioner for Patents	Filing Date	August 17, 2000	
Washington, D.C. 20231	Group Art Unit	1653	
	Examiner Name	A.A. Mohamed	
Ris .	Title: Methods and comp	ositions for reducing serum phosphate levels	

This is in response to the Restriction Requirement dated January 9, 2003. The Restriction Requirement set forth a one-month time period for response, making a response due on or before February 9, 2003. Accordingly, this response is timely filed.

I. REMARKS

In the Restriction Requirement, the Examiner required election of one of the following groups of claims:

Group I: Claims 1-11, drawn to a peptidic compounds and composition thereof comprising one or

more moieties that are phosphorylated in vitro or in vivo by physiologic enzymes and a

method of reducing a phosphate level thereof;

Sir:

Group II: Claims 12-16, drawn to a method of treating hyper phosphatemia in an individual by

administering the composition recited in claim 12;

Group III: Claim 17, drawn to a method of increasing incorporation of phosphorus into bone in an

individual by administering the composition recited in claim 17;

Group IV: Claim 18, drawn to a method of increasing bone strength in an individual by

administering the composition recited in claim 18; and

Group V: Claims 19, drawn to a method of treating a bone disease in an individual by administering

the composition recited in claim 19.

Applicants hereby elect to prosecute the claims of Group II (claims 12-16), with traverse. Applicants expressly reserve the right under 35 USC §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of this application.